MEDIA RELEASE: 12 August 2020
Melbourne-based Entoura is now accepting orders for its EMC THC 26 OIL product.
Available as a THC dominant product (THC 26mg/mL) the Entoura formulation is a Whole Plant Extract.
Importantly, the Entoura EMC THC 26 Oil is grown, extracted, and manufactured in Australia by the Cann Group, joining a very select group of Australian made products in the Australian Medicinal Cannabis market. The addition of a THC dominant product rounds out Entoura’s product range portfolio.
This is great news for prescribers hoping to access an Australian grown and manufactured THC dominant oil for approved patients struggling to manage their conditions with traditional pharmaceuticals. For practitioners who wish to learn more about Entoura’s products, please register to the Entoura Cannabis Support Portal via the website.
Cann Group CEO Peter Crock said “We are very pleased to be working with Entoura to expand their product range to deliver locally grown and manufactured product to Australian patients and look forward to developing this partnership with Entoura”.
Entoura was established by Professor Ian Brighthope, who over 40 years ago founded Nutrition Care Pharmaceuticals, a leader in the formulation and manufacture of therapeutic nutraceutical medicines. Entoura is committed to the development of high-quality innovative therapeutics that are supported by outstanding research programs, validated with clinical evidence and disseminated via exceptional education programs.
Entoura is active in the Medicinal Cannabis industry, supporting medicinal cannabis research, education, manufacturing and patient access
About Cann Group
Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. The company has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation facility near Mildura, Victoria. Cann Group has executed collaboration agreements that have enabled it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products. Learn more about Cann Group at www.canngrouplimited.com
For further media information about Entoura and its products, or for help in access, please contact Entoura.
For further information about the Cann Group please contact:
Cann Group Limited
+61 3 9095 7088